PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

NCT07014215 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
Resistance to Immunotherapy

Interventions

DRUG: Sintilimab combined with Bevacizumab and tafolecimab

Sponsor

Anhui Provincial Cancer Hospital